lymphoma 167, 178 \200\22380, 755 adult-type chronic 590 \200\2231 myeloid (granulocytic) leukemia 626 drug-related 38, 40, 50, 94, 102 afi brinogenaemia 482 \200\2233 agammaglobulinaemia, endocrine disease 36 Fanconi 395, 415, 594 \200\2235 folate defi ciency 26, 41, X-linked 548 age-adjusted IPI 187 aggressive lymphomas anti-D 422, 578, 579 antiemetics 694 \200\2236 antifungals 442 \200\2234, 687 antiphospholi pid syndrome 48 \200\2239 gastrointestinal disease 40 iron defi ciency 42 \200\2235 joint disease 38 \200\2239 leucoe rythroblastic 101 liver disease 41 megaloblastic 46, 48, 50 microangiopathic 198 \200\223208 aggressive NK-cell large granular lymphocyte leukemia 176 aggressive systemic 534, 535 antiretrovirals 556 antithrombin defi ciency 530, 531 mastocytosis 312, 319 aplastic anemia 102 \200\2233, aggressive T-cell large haemolytic 96, 576 neonatal haemolytic 572, 393, 395, 414 granular lymphocyte leukemia 175 aprotinin 470 argatroban 655 arsenic trioxide 135 574, 576 neonates 568 \200\2239 AIDS 552 \200\2233 814 INDEX transfusion-associated massive blood loss 508 neonates 585 surgery 28 \200\2239, 467, 506 \200\2237 therapeutic pr oducts aspergillosis 442 \200\2234 aspirin 502 asymptomatic GvHD 775 transfusion haemosiderosis 77, 110 \200\22311 (smoldering) myeloma 25, 332 \200\2234 470 \200\2231 transfusion-related acute thrombolytic therapy overdose 651 blood and blood products bacterial contamination ataxia telangiectasia 548 ATRA syndrome 135 atypical chronic lung injury 638 transfusion transmitted infections 774 \200\2235 see also blood and blood lymphocytic leukemia 161 638 products CMV-negative blood atypical chronic myeloid leukemia 252, 253 \200\2234 atypical mycobacteria 687 Auer rods 12 5, 126, 621 autoantibody mediated Bloom syndrome 595 body surface area nomogram 806 bone fractures 23 bone marrow fi brosis 2 95 harvesting 388, 408 \200\2239 mastocytosis 319 bone tumors 608 bortezomib/ products 420, 563, 765 irradiated products 776 issue and administration 763 haemolysis 94 autohaemolysis test 85 autoimmune disorders stem cell transplantation 420 \200\2232 see also specifi c products 394, 396 and blood transfusion blood counts 560 \200\2231, 746, autoimmune haemolytic anemia 98 \200\2239 dexamethasone 716 \200\22317 812 autoimmune neutropenia brain tumors 396, 608 breast cancer 393 bruising 20 \200\2231 Bruton tyrosine kinase defi c iency 548 B-symptoms 185 Burkitt cell leukemia 144 Burkitt-like lymphoma 616 Burkitt lympho ma 200, 201, 206, 393, 616, 618, 755 blood fi lm 746 blood-grouping 762 blood loss, see bleeding blood products, see blood and b lood products blood transfusion 759 \200\22381 15, 601 autologous stem cell transplantation 389, 402, 449 azo compound poisoning 634 acute transfusion reactions 638 \200\22340, 641 Better Blood Transfusion B babesiosis 82 basopenia 120 basophilia 120 basophilic stippling 33 basophils 120 B cells 118 BCR-ABL+ acute initiatives 764 burns 82 burr cells 33, 35 children 562 \200\2234 consent for 764 delayed transfusion reaction 642 C Candida infections 442, history 2 HLA-related issues 757 hospital transfusion committee 764 lymphoblastic leukemia 144 444, 549 cardiac haemolysis 82 cardiopulmonary bypass hospital transfusion policy BEACOPP/escalated BEACOPP 712 BEAM/LEAM 714 \200\22315 benign familial neutropenia 763 502 hospital transfusion team cardioversion 536 caspofungin 443, 444 Castleman disease 364, 788 Castleman-like disease 36 4 CD number 752 central indwelling catheters 764 intra-operative cell salvage 777 15 -lactam antibiotics 502 Better Blood Transfusion issue and administration blood and blood products 763 Jehovah \200\231s Witnesses initiatives 764 B-fi ndings 316 bilirubin 582 Binet staging 162 bird-headed dwarfi sm 598 bite cells 33 Bla ckfan \200\223Diamond 686 central nervous system, 780 \200\2231 see CNS laboratory requests 762 massive 468, 658 \200\22360 maximum surgical blood ordering schedul e 778 post-transfusion purpura C-fi ndings 316 \200\22317 Chediak \200\223Higashi syndrome 486, 603 chemotherapy anemia, see Diamond \200\223 Blackfan anemia administration 692 \200\2233 emesis and antiemetics 492, 643 bleeding 466 \200\2238 sickle-modifying therapy anticoagulant-induced 694 \200\2236 62 467, 515 extravasation 700 \200\2233 intrathecal 698 \200\2239 traceability 763 transfusion-associated circulatory overload 639 heparin-induced 510 \200\22311, 704 chemotherapy protocols laboratory investigations 710 \200\22344 ABVD 711 469 815 INDEX Crohn \200\231s disease 394 cross-matching 762 Crow \200\223Fukase syndrome 364 cryoglobuli naemia 363 cryoprecipitate 658, 660, chronic neutrophilic leukemia 304 chronic NK-cell large BEACOPP/escalated BEACOPP 712 BEAM/LEAM 714 \200\22315 bortezomib/ granular lymphocyte leukemia 176 \200\2237 dexamethasone 716 \200\22317 ChlVPP 720 CHOP (21 and 14) 771 chronic renal failure 34 \200\2235, cryopreserved stem cells 498 412, 416 \200\22317 CTD/CTDa 726 \200\2237 Cushing \200\231s syndrome 36 cutaneous mastocyt osis chronic severe lymphopenia 15 718 \200\22319 chronic thromboembolic CODOX-M/IVAC R pulmonary hypertension 518 722 \200\2234 312, 313 \200\22315 CTD/CTDa 726 \200\2237 DHAP R 728 \200\2239 ESHAP R 730 \200\2231 FC R 732 ICE R 733 lenalidomide/ cyanotic congenital heart ciclosporin 424 \200\2236 cirrhosis 109 cladribine 688 classical Hodgkin disease 632 cyclical neutropenia 15, 116, 600 cytogenetics 754, 755 cytomegalovirus (CMV) blood products 420, lymphoma 214 \200\22315, 221 \200\2233 CLL-score 160 clonality assessment 753 Clostridium p erfringens 82 clot formation 456 clotting factor concentrates dexamethasone 734 mini-BEAM R 736 MPT 735 NORDIC schedule 737 PMitCEBO 738 R-Bendamustine 739 R-CHOP 740 R -CVP and CVP 741 R-high-dose cytarabine 563, 765 neutropenic sepsis 687 transplant patients 446 \200\2237 470 D dabigatran 516 \200\22317, 707 dactylitis 57 danaparoid 655 Darier \200\231s sign 313 D-d imer assay 518, 519 deep vein thrombosis clotting tests 458 \200\22360 CMV, see cytomegalovirus CNS 737 leukemia 135, 144 lymphoma 212 \200\22313 coagulation system 456, rituximab monotherapy and maintenance therapy 742 R-maxi-CHOP 737 Stanford V 743 \200\2234 457, 459, 461 coagulation tests 458 \200\22360 codeine 671 CODOX-M/IVAC R 518 \200\22321 children, see pediatrics chloroma 135, 622 ChlVPP 720 CHOP (21 and 14) 718 \200\22319 Chris tmas disease 476 chronic benign neutropenia deferasirox 77, 111, 245 deferiprone 77, 111, 245 dendritic cell histiocytosis 722 \200\2234 cold antibody induced haemolysis 98 (Langerhans cell) 628 \200\2239, 793 cold haemagglutinin disease desferrioxamine 77, 110, 100 combined 15, 600 245 chronic eosinophilic desmopressin 470 dexrazoxane 701 DHAP R 728 \200\2239 diabetes mellitus 36 Diamond \200 \223Blackfan anemia immunodefi ciency disorders 546 \200\2238 leukemia, not otherwise categorized 308 \200\2239 chronic granulomatous disease 395, 603 common variable immunodefi ciency 549 compatibility testing 762 complement defi ciency 603 conditioning 389, 399, chronic idiopathic neutropenia 15 chronic infl ammatory demyelinating polyneuropathy 394 395, 590 \200\2231 diamorphine 671 diclofenac 670 diff use cutaneous 414 \200\22315 reduced intensity 389, mastocytosis 313 415 chronic lymphocytic diff use large B-cell congenital amegakaryocytic thrombocytopenia 596, 598 leukemia 158 \200\22365, 166, 392, 755 lymphoma 198, 201, 204, 392, 617, 618 DiGeorge syndrome 548 dihydrocodeine 671 dimorphic re d blood chronic mucocutaneous congenital candidiasis 549 dyserythropoietic anemia 588 \200\2239 chronic myeloid leukemia 148 \200\22356, 392, 395, 414, 755, 808 cells 33 congenital intrinsic factor Diphyllobothrium latum defi ciency 50 chronic myelomonocytic leukemia 230, 252 \200\2233 chronic myeloproliferative 47, 633 contamination injury 708 contraceptive pill 531, 532 Cooley \200\231s anemia 76 \200\2237 c ord compression 662 crenated red cells 33 disodium pamidronate 644, 645 disorder, see myeloproliferative neoplasms disseminated intravascular coagulation 467 \200\2238, 494 \200\2235, 648 \200\22350 816 INDEX FEIBA 471 Felty syndrome 15, 116, anemia of prematurity Down syndrome 620, 570 624, 625 601 fentanyl 671 ferritin (serum) 9, 43, 107 fetal hemoglobin 54 inappropriate excess 10 myelodysplastic drug-induced conditions anemia in gastrointestinal syndromes 246 \200\2237 sickle-modifying therapy disorders 40 anemia of chronic disorders 38 aplastic anemia 102 folate defi ciency 48 haemo lysis in G6PD defi ciency 88, 89 haemolytic anemia 94 megaloblastic anemia 50 neutropenia 1 5, 116 platelet dysfunction hereditary persistent 62 80, 81 FGFR1 308 fi brin 456 fi brinogen concentrate 658 fi brinogen level 459 fi brinolysi s tests 460 fi brin stabilizing factor defi ciency 483 Escherichia coli 540, 606 ESHAP R 730 \200\2231 essential thrombocythaemia 281 \200\2238 EUTOS score 151 Evans syndrome 601, 604 Ewing sarcoma 396 exchange transfusions fi fth disease 632 fi sh oils 502 5q- syndrome 242 fl udarabine 688 foamy macrophages 634 f olate defi ciency 26, 41, 465, 502 562 \200\2233 red cell defects in children extracorporeal 577 photopheresis 430 thrombocytopenia 468, extracutaneous 492 \200\2233 mastocytoma 312, 319 Duncan syndrome 632 Durie \200\223Salmon staging 48 \200\2239 extravasation 700 \200\2233 eye follicular lymphoma 166, 190, 192, 194 \200\2236, 393 system 344 fundus examination 4 ocular lymphoma 212 sickle cell anemia 58 Dynamic IPSS-plus 297 dysfi brinogenaemia 483 dyskeratosis congenita 547, Follicular Lymphoma International Prognostic Index 188 596 \200\2237 fractures, pathological 23 fragmented red blood F F2G20210A 530, 531 factor II defi ciency 484 factor V antibodies 500 factor V defi ciency 484 E 8p11 myeloproliferative cells 33 Franklin disease 378 fresh frozen plasma 470, 564, 658, 660, 770 \200\2231 full blood count 746, 812 fundus examination 4 fungal infections 442 \200\2234, syndrome 308 elliptocytes 33 elliptocytosis, hereditary 87 embryonal tumors 608 emergencies 635 \200\223 66 emesis, chemotherapy- factor V Leiden mutation/ polymorphism 530, 531 factor VIIa 456 factor VII defi ciency 483 factor VIII inhibitors 687 related 694 \200\2235 endocrine disease 36 enteropathy type T-cell lymphoma 199 eosinophili a 119, 306 G Gaisbock \200\231s syndrome 10 gastric MALT lymphomas 499 \200\223501 factor IX 456 factor IXa 456 factor X 456 190, 197 aberrant T lymphocytes gastrointestinal disease 40 Gaucher disease 634, 310 defi ciency 484 eosinophilic granuloma, see Langerhans cell histiocytosis factor Xa 456 factor XI defi ciency 482 factor XIIIa 456 factor XIII defi ciency 483 factor assays 459 familial erythrophagocytic lymphohistiocytosis 629 \200\22330 784 \200\2235 gentamicin dosage nomogram 807 eosinophilic leukemia 119 eosinophilic syndromes and germ-cell tumors 393, 396 giant cavernous neoplasms 306 \200\22310 Epstein-Barr virus 122, 632 erythrocyte sedimentation rate (ESR) 2 4, 747 erythrocytosis 264 \200\2236 idiopathic 265, 280 primary 264 red cell mass and plasm a haemangioma 487 giant lymph node hyperplasia (Castleman disease) 364, 788 familial mastocytosis 313 Fanconi anemia 395, 415, glandular fever 632 Gleich syndrome 309 globin chains 54 globin genes 54 glucose phosphate 594 \200\2235 Fanconi syndrome 102 favism 89 FC R 732 FDG-PET 210, 217 \200\22318 febrile non-haemolyt ic volume 267 relative 264, 265, 279 secondary 264 \200\2235, 278 isomerase defi ciency 92 glucose-6-phosphate erythropoietin 10 \200\22311 transfusion reactions 639 \200\22340 dehydrogenase (G6PD) defi ciency 88 \200\22390 anemia in renal disease 34 817 INDEX HIV 200, 479, 552 \200\2234, 556 \200\2237 HLA typing 756 \200\2237 Hodgkin lymphoma 184, 2 14 \200\22325, 393, 395, 616 HbC disease 66, 81 HbC trait 66, 81 HbD/ thalassaemia 81 HbD disease 66, 81 HbDPunjab 65 HbD trait 66, 81 HbE/ thalassaemia 81 HbE/ thalassaemia 66, graft-versus-host disease 391, 428 \200\22336, 563 prophylaxis 424 \200\2237 transfusion-as sociated home-brew 111 hookworms 633 Howell \200\223Jolly bodies 33 HTLV-1 178 human leucocyte antig en (HLA) typing 756 \200\2237 Hurler \200\223Scheie syndrome 775 graft-versus-leukemia eff ect 388 granulocyte transfusions 564 79, 81 gray platelet syndrome HbE disease 66, 81 HbE trait 66, 81 HbF 54 485, 486 395 group and save 762 group, screen and save procedure 778 Hurler syndrome 395 hydroxycarbamide 62 hyperadrenalism 36 hyperbilirubinaemia 582 \200\223 3 hypercalcaemia 644 \200\2235 hypercoagulable states 22 hypereosinophilic hereditary persistent 80, 81 HbH disease 72, 81 HbLepore 79, 81 HbM 95 HbOArab 65 H bodies 33 HbS/ thalassaemia 65 HbS C 65 HbSD 65 HbSOArab 65 HbSS 56 \200\22360, 81 HbS solubility test 30 HCV 479 heavy chain disease 25, 378 Heinz bodies 33, 68 HEMPAS 751 Henoch \200\223Sch nlein purpura H HAART 556 haematinic assays 747 haematocrit 264 hematological syndrome 119, 308 idiopathic 309 \200\22310 hypergammaglobulinaemia investigations 745 \200\22357 haematopoietic stem cell transplantation, see stem cell trans plantation 646 \200\2237 hyper IgE syndrome 603 hyper IgM syndrome 548 hyperparathyroidism 36 hypersplenism 492 hype rviscosity 646 \200\2237 hypoadrenalism 36 hypofi brinogenaemia 482 \200\2233 hypogammaglob ulinaemia haemochromatosis 107 hemoglobin (Hb) abnormalities 54 \200\2235 electrophoresis 747 elevated 10 \200\22311 genetics of productio n 54 normal values 561 patterns in hemoglobin 504 550 heparin 510 \200\22311, 536, 704 \200\2235 hypopituitarism 36 hypoplastic myelodysplastic overdosage 652 heparin-induced disorders 81 syndrome 242 thrombocytopenia 512, 542 \200\2233, 654 \200\2235, 704 heparin-like inhibitors 500 hepatoc ellular carcinoma unstable 68 see also Hb headings hyposplenic blood fi lm 33 hyposplenism 551 hypothyroidism 36 haemolytic disease of the newborn 578 \200\22380 109 haemolytic syndromes 52 \200\2233 haemolytic uraemic hereditary acanthocytosis 83 hereditary elliptocytosis 87 hereditary haemorrhagic telangiec tasia 487 hereditary persistence I ibuprofen 670 ICE R 733 idiopathic cytopenia of uncertain (undetermined) signifi cance (ICUS) 235 idiopathic erythrocytosis syndrome 540, 606 \200\2237 haemophagocytic lymphohistiocytosis 629 \200\22330 of fetal hemoglobin 80, 81 haemophagocytic syndromes 629 \200\22330 hereditary spherocytosis hemophilia 454 84 \200\2236 A and B 476 \200\22380 Hermansky \200\223Pudlak syndrome 486 haemorrhagic disease of the newborn 488, 584 265, 280 idiopathic hypereosinophilic herpes simplex virus 687 herpes zoster virus 687 haemosiderinuria 750 haemostasis assessment syndrome 309 \200\22310 idiopathic myelofi brosis prophylaxis 688 454 292 \200\223300 hexokinase defi ciency 92 highly active antiretroviral therapy (HAART) 556 hairy cell leukemia idiopathic (variant) 166, 170 \200\2233 thrombocythaemia 281 \200\2238 idiopathic Ham \200\231s test 104, 751 Hand \200\223Sch ller \200\223Christian disease 628, 793 hapte n mechanism 94 haptoglobin 748 Hasenclever score 221 HbBart \200\231s hydrops fetalis histiocytic necrotizing lymphadenitis 789 histiocytic syndromes thrombocytopenic purpura, see immune (idiopathic) thrombocytopenic purpura 628 \200\22330 histiocytosis X (Langerhans cell) 628 \200\2239, 793 history taking 2 \200\2233 73, 81 IgA defi ciency 549 818 INDEX J JAK2-V617F 260 \200\2231, 264, acute promyelocytic 135 adult T-cell 167, 178 \200\22380, IgD myeloma 362 IgE myeloma 362 IgM myeloma 362 immature platelet fraction 755 281, 292 adult-type chronic jaundice, neonatal 89, 582 Jehovah \200\231s Witnesses 780 \200\2231 Job syndrome 603 joint disease 38 \200\2239 juvenile (chronic) myeloid (granulocytic) 626 464 immune cytopenias 394 immune (idiopathic) aggressive NK-cell large granular lymphocyte 176 thrombocytopenic purpura 27, 468, 492, 604 \200\2235 myelomonocytic leukemia 252, 254, 625 aggressive T-cell large granular lymphocyte 175 immunodefi ciency juvenile rheumatoid arthritis 632 acquired 550 \200\2231; see atypical chronic also HIV lymphocytic 161 atypical chronic myeloid congenital syndromes 546 \200\2239 K Kaposi sarcoma 554, 557 Karnofsky performance 252, 253 \200\2234 biphenotypic 129 Burkitt cell 144 childhood 608, 612 \200\22314, immunophenotyping 752 \200\2233 immunoproliferative small intestinal disease 378 inappropriate status 804 620 \200\2232, 624 \200\2236 erythropoietin excess 10 karyotyping 754, 755 Kasabach \200\223Merritt syndrome 576 Kawasaki disease 633 kernicterus 578 Kikuchi ( \200\223Fujimoto) disease chronic eosinophilic, not otherwise categorized 308 \200\2239 indolent lymphoma 190 \200\2237 indolent systemic chronic lymphocytic mastocytosis 312, 319 infectious mononucleosis 158 \200\22365, 166, 392, 755 chronic myeloid 148 \200\22356, 392, 395, 414, 755, 808 632 789 innocent bystander mechanism 94 KIT mutations 261, 312 \200\22313 Kleihauer test 748 Kostmann syndrome 395, chronic myelomonocytic insect bites 82 international normalized 230, 252 \200\2233 596 chronic neutrophilic 304 chronic NK-cell large ratio (INR) 514 International Prognostic kwashiorkor 633 granular lymphocyte 176 \200\2237 CNS 135, 144 eosinophilic 119 hairy cell (variant) 166, Index 187 \200\2238 L Langerhans cell International Prognostic Score 221 International Prognostic Scoring System (IPSS/ IPSS-R) 238 \200\2239, 296 \200\2237, 371 histiocytosis 628 \200\2239, 793 large cell anaplastic 170 \200\2233 lymphoma 617, 618 large granular lymphocyte investigations 676 juvenile (chronic) International Staging leukemia 174 \200\2237 lazy leucocyte syndrome myelomonocytic 252, 254, 625 System 344 internet resources 796 \200\223801 intra-operative cell salvage 602 \200\2233 large granular lymphocyte lead poisoning 82, 633 leishmaniasis 633 lenalidomide/ 174 \200\2237 777 mast cell 312, 319 mature B-cell acute intrathecal chemotherapy 698 \200\2239 dexamethasone 734 Lesch \200\223Nyhan syndrome 50 Letterer \200\223Siwe disease lymphoblastic 144, 755 intravenous drug users 522 intravenous NK-cell large granular lymphocyte 167, 176 \200\2237 immunoglobulin 563, 772, 773 628, 793 leucocytosis 12 leucoerythroblastic anemia 101 intravenous iron 45 intrinsic factor defi ciency 50 invasive aspergillosis 442 \200\2234 in vasive candidiasis 442, 444 IPSID 378 iron chelation therapy 77, plasma cell 25, 362 prolymphocytic 166, leucoerythroblastic blood 168 \200\2239 fi lm 12 leucopenia 14 leucostasis 663 leukemia smoldering chronic lymphocytic 162 T-cell acute lymphoblastic 110 \200\22311, 244 \200\2235 144, 755 iron defi ciency 42 \200\2235, 633 iron overload 107 \200\2239, acute lymphoblastic T-cell large granular lymphocyte 167, 174 \200\2235 138 \200\22345, 392, 395, 414, 612 \200\22314, 755 110, 111 irradiated blood products acute myeloblastic T-cell prolymphocytic 776 IVAC 723 124 \200\22335, 225, 392, 395, 414, 620 \200\2232, 755 167 819 INDEX marginal zone 190, 192, massive splenomegaly 5 mast cell disease, see mastocytosis leukaemoid reaction 12, 197 115 mature T-cell 198, 201 mediastinal large B-cell Liley chart 580, 581 Lille prognostic scoring mast cell leukemia 312, 198, 201 319 system 296 liver biopsy 108 liver disease 41, 82, 496 \200\2237 low-molecular-weight hepari n 510, 704 \200\2235 lupus anticoagulant 534 \200\2235 lupus erythematosis 394 lymphadenopa thic mycosis fungoides 199, mast cell sarcoma 312, 319 mastocytosis 312 \200\22313, 632 cutaneous 312, 313 \200\22315 s ystemic 312, 316 \200\22322 201, 205 \200\2236 nodal marginal zone 190, 197 non-Hodgkin 182 \200\2236, mature B-cell acute 210, 393, 395, 557, 616 \200\22317, 618, 755 lymphoblastic leukemia 144, 755 ocular 213 peripheral T-cell 198 \200\2239, mature B-cell neoplasms mastocytosis with eosinophilia 319 lymphadenopathy 6 \200\2237 lymph node biopsy 7 lymph no de enlargement 4 lymphoblastic lymphoma 183 201, 617 mature T-cell lymphoma post-transplantation 200 \200\2231 precursor 198, 201 mature T-cell neoplasms 184 maximum surgical blood ordering schedule 778 B-lymphoblastic 201, 617, 618 200, 206, 393 lymphocyte-depleted precursor May \200\223Hegglin anomaly T-lymphoblastic 201, 617, 618 485, 486 Hodgkin lymphoma 215 Mayo Stratifi cation of Myeloma and Risk- Adapted Therapy (mSMART) 344 MCL International lymphocyte rich classical Hodgkin lymphoma 215, 216 response criteria 209 small lymphocytic 190, 192, 194 \200\2236 lymphocytes 118, 561 lymphocytosis 13, 118 lymphoid neoplasms, splenic marginal zone 166, 190 \200\2231, 192, 197 Prognostic Index 188 MDS/MPD unclassifi able T-cell rich B-cell 198 transplant conditioning WHO classifi cation 182, 183 \200\2234 252, 254 \200\2235 regimens 415 mean cell volume 9, 561 mean platelet volume 464 mediastinal large B-cell lymphoma 198, 201 lymphoma very aggressive 200, 206 adult T-cell 167, 178 \200\22380, lymphopenia 15, 118 lymphoplasmacytic lymphoma 191 755 aggressive 198 \200\223208 anaplastic large cell 199, Mediterranean thrombocytopenias 485 201 medulloblastoma 393 megaloblastic anemia 46, angio-immunoblastic T-cell 199, 201 Burkitt 200, 201, 206, 393, 616, 618, 755 M McLeod phenotype 97 macrocytic red blood 48, 50 metal heart valves 536, 537 methaemoglobin 95 methaemoglobinaemia 95 methotrexate 424 MHC c lass II defi ciency 547 microangiopathic Burkitt-like 616 childhood 608, 616 \200\22318 CNS 212 \200\22313 diff use large B-cell 198 , 201, 204, 392, 617, 618 cells 33 maculopapular cutaneous mastocytosis/urticaria pigmentosa 313 maize-based beverages 111 major histocompatibility complex (MHC) 756 haemolytic anemia 96, 576 enteropathy type T-cell microcytic red blood 199 malaria 82 malignant histiocytosis 630 MALT lymphoma 190, 197 mantle cell lymphoma 166, 198 , 201, 205, 393 cells 33 FDG-PET 210, 217 \200\22318 follicular 166, 190, 192, mini-BEAM R 736 minimal residual disease 194 \200\2236, 393 144 gastric MALT 190, 197 HIV-associated 200 Hodgkin 184, 214 \200\22325, 393, 395, 616 mixed cellularity Hodgkin marasmus 633 marble bone disease lymphoma 215 mixed cryoglobulinaemia (osteopetrosis) 395, 598, 794 363 indolent 190 \200\2237 large cell anaplastic 617, mixing studies 459 molecular cytogenetics 754 monoclonal antibodies 752 monoclonal B-cell march haemoglobinuria 82 marginal zone lymphoma 618 lymphoblastic 200, 206, 190, 192, 197 Maroteaux \200\223Lamy syndrome 395 massive blood loss 508 massive blood tran sfusion 393 lymphocytosis 161 monoclonal gammopathy of undetermined signifi cance 25, 328 \200\22330 lymphoplasmacytic 191 MALT 190, 197 mantle cell 166, 198, 201, 205, 393 468, 658 \200\22360 820 INDEX stem cell transplantation nitrate poisoning 643 nitrobenzene poisoning 634 NK-cell large granular monocytes 121 monocytopenia 121 monocytosis 121 mononucleosis syndromes 392, 415 myeloid and lymphoid neoplasms lymphocyte leukemia 167, 176 \200\2237 FGFR1 rearrangement 122 308 NK-cell neoplasms 184 nodal marginal zone monosomy 7 syndrome PDGFRA/B rearrangement 625 307 lymphoma 190, 197 monospot test 122 morphine 671 mouth examination 4 MPL-W515L/K 261, 281, myeloma 25, 362, 393, 415, 502; see also multiple myeloma nodular lymphocyte- predominant Hodgkin lymphoma 215, 216, 223, 393 myeloperoxidase defi ciency 292 603 nodular sclerosing Hodgkin MPN \200\223 unclassifi able 323 MPT 735 MRI 108 mucopolysaccharidoses myeloproliferative lymphoma 215 neoplasms 16, 258 \200\22361, 755 non-Hodgkin lymphoma 182 \200\2236, 210, 393, 395, 557, 616 \200\22317, 618, 755 395 non-immune haemolysis multiple myeloma 336 \200\22359 N nausea and vomiting, 82 \200\2233 asymptomatic non-nucleoside reverse (smoldering) 25, 332 \200\2234 transcriptase inhibitors 556 grading 695 bone disease 337 clinical features 337 diagnostic criteria 340 follow-up 355 investigations 338, necrotizing enterocolitis non-secretory myeloma 563 362 needlestick injuries 708 \200\2239 neonates NORDIC schedule 737 normal ranges 810 \200\22312 NSAIDs 502 nucleophosmin gene 130 nucleosi de reverse alloimmune 339 \200\22340 thrombocytopenia (NAIT) 485, 586 \200\2237 management and therapies 348 \200\22356 anemia 568 \200\2239 bleeding 585 blood component therapy 562 \200\2234 transcriptase inhibitors 556 prognosis 342, 359 response assessment nutritional disorders 633 344 \200\2238 staging systems 344 multiple sclerosis 394 mycophenolate mofetil 426 mycosis fungoides 199, haemolytic anemia 572, 574, 576 O octaplas 771 ocular lymphoma 213 omega-3 fatty acids 502 Omenn syndrome 547 online resour ces 796 \200\223801 opioid analgesics 671 opportunistic infections haemolytic disease 578 \200\22380 201, 205 \200\2236 myelodysplastic/ haemorrhagic disease 488, 584 myeloproliferative diseases 252 \200\2235 haemostasis 584, 585 isoimmune neutropenia myelodysplastic syndromes 601 228 \200\22351 jaundice 89, 582 polycythaemia 566 \200\2237 red cells 560 red cell transfusion 562 \200 \2234 sickle cell screening 60 thrombocytopenias 485 white cells 560 neuroblastoma 396 neur ological examination 4 neutropenia 14 \200\22315, 116 \200\22317 children 395, 624 \200\2236 classifi cation 230, 231 clinical features 234 \200\2237 hypopl astic 242 indications for stem cell transplantation 392, 395 553 optic fundi 4 oral contraceptive pill 531, 532 organ transplantation, lymphoproliferative disease following 200 \200\2231 isolated del(5q) 231, 242 karyotyping 755 management 244 \200\2237 with myelofi brosis 242 prognostic factors 236, Ormond \200\231s disease 792 orotic aciduria 50 Osler \200\223Weber \200\223Rendu syndrome 487 childhood 600 \200\2231 congenital 597 IV antibiotics 682 \200\2233 prophylaxis 680 sepsis 636 \200\2237, 684, 686 \200\2237 neutrophilia 12 \200\22313, 114 \200\22315 neutrophils 11 4, 561, osmotic fragility test 84 \200\2235 osteoarthritis 38 osteogenic sarcoma 396 osteopetrosis 395, 598, 238 \200\22340 response criteria 250 \200\2231 secondary 242 unclassifi ed 231 794 myelofi brosis 602 \200\2233 osteosclerotic myeloma in myelodysplastic syndromes 242 primary (with myeloid new oral anticoagulant drugs 516 \200\22317, 707 Niemann \200\223Pick disease 364 \200\2235 ovarian cancer 393 overanticoagulation 467, metaplasia) 292 \200\223300 634, 786 515 821 INDEX \200\230washed \200\231 769 plerixafor 411 PMitCEBO 738 Pneumocystis jirovecii pneumonia 6 86 parvovirus B19 infection oxidative haemolysis 82 oxycodone 671 oxygen therapy 82 592, 632 Paul \200\223Bunnell test 122 PDGFRA/B 307 Pearson syndrome 598 pencil cells 33, 44 pentost atin 172 perianal infection 686 peridontal infection 686 peripheral arterial thrombosis 537 peripheral blood stem P pediatrics prophylaxis 688 POEMS syndrome 364 \200\2235 poisons 82, 633 \200\2234 polychromatic red blood blood component therapy 562 \200\2234 blood counts 560 \200\2231 cancer 608 \200\22310 cong enital bone marrow failure syndromes 596 \200\2238 congenital cells 33 polycythaemia children 566 \200\2237 primary proliferative (rubra vera) 10 spurious (stress) 10 vera 264 \200\22375 porphyrias 790 \200\2231 post-exposure prophylaxis cell mobilization and harvesting 388, 410 \200\22311 peripheral T-cell lymphoma 198 \200\2239, 201, 617 dyserythropoietic anaemias 588 \200\2239 haemolytic uraemic syndrome 606 histiocytic syndro mes pernicious anemia 46, 47 PET 210, 217 \200\22318 petechiae 307 PFA-100 464 phenindione 515 phenotyped red cells 778 Philadelphia chromosome 708 post-thrombotic syndrome 518 628 \200\22330 post-transfusion purpura hyperbilirubinaemia 492, 643 post-transplant 582 \200\2233 139 immune (idiopathic) lymphoproliferative disease 200 \200\2231 phosphofructokinase defi ciency 92 thrombocytopenic purpura 604 \200\2235 post-viral aplastic anemia phosphoglycerate kinase indications for stem cell transplantation 395 \200\2236 Jehovah \200\231s Witnesses 781 leu kaemias 608, 612 \200\22314, 102 defi ciency 92 post-viral neutropenia 14 precursor B-lymphoblastic lymphoma 201, 617, 618 physical examination 4 physiological haemolysis 572 physiological jaundice 620 \200\2232, 624 \200\2236 89, 582 lymphomas 608, 616 \200\22318 myelodysplastic precursor T-lymphoblastic lymphoma 201, 617, 618 pregnancy Pickwickian syndrome 10 pituitary disorders 36 plasma cell leukemia syndromes 624 \200\2236 neutropenia 600 \200\2231 neutrophil disorders 25, 362 plasmacytoma 25, 366 \200\2237 plasma viscosity 24, 746 platelets 462 acute myeloblastic leukemia 134 602 \200\2233 normal ranges 812 polycythaemia 566 \200\2237 red cell aplasia 590 \200\2231, anemia 26 anticoagulation 536 disseminated intravascular acquired dysfunction 502 \200\2233 592 \200\2233 aggregation 464 children 560 \200\2231 congenital dysfunction coagulation 648 red cell defects 574 \200\2235, ESR 24 essential 576 \200\2237 red cell transfusion 562 \200\2234 systemic disease 632 \200\2234 transient 486 thrombocythaemia 287 count 462, 561 drug-related dysfunction hemophilia diagnosis 480 polycythaemia vera 275 sickle cell anemia 58, 60 thalassaemia scre ening 78 thrombocytopenia 27, erythroblastopenia of childhood 592 \200\2233 465, 502 elevated count 16 \200\22317 granules 464 increment 679 laboratory tests 462 \200\2235 morp hology 464 nucleotides 464 PFA-100 464 pregnancy 27 reduced count 18 \200\22319 refractorin ess 678, 769 RIPA 464 size 464 systemic disease 502 transfusion 470, 564, 659, see also neonates pain management 670 \200\2232 pamidronate 644, 645 paracetamol 670 paraparesis 662 paraprot ein, serum/ 492 thrombophilia 531, 535 \200\2236 venous urine 25 thromboembolism 536 paraproteinaemias 326, 502 parathyroid disorders 36 parenteral iron 45 paroxysmal cold von Willebrand disease 474 warfarin 515, 536 haemoglobinuria 98 paroxysmal nocturnal prematurity anemia 570 red cells 560 haemoglobinuria 104 \200\2235, 393, 537, 751 660, 678, 768 \200\2239 822 INDEX R racial neutropenia 15 Rai modifi ed staging 161 R-Bendamustine 739 R-CHOP 740 R-CVP and C VP 741 reactive eosinophilia 307 reactive thrombocytosis Rh (D) antigen 578 rheumatoid arthritis 38, prenatal diagnosis hemophilia 480 sickle cell anemia 60 thalassaemia 78 394 juvenile 632 R-high-dose cytarabine presenting symptoms 2 \200\2233 priapism 58 primary erythrocytosis 264 primary immunodefi c iency 737 Richter \200\231s syndrome 165 ristocetin-induce platelet agglutination (RIPA) 464 395 290 rituximab, monotherapy and maintenance therapy 742 rivaroxaban 517, 707 R-maxi-CHOP 737 rod cells 33 rouleaux 33 primary myelofi brosis recombinant factor VIIa 292 \200\223300 471 red cells primary proliferative polycythaemia 10 aplasia 106, 590 \200\2231, 592 \200\2233 children 560, 574 \200\2235, primary systemic amyloidosis 380 \200\2236 576 \200\2237 primary thrombocythaemia distribution width 43 frozen 765 % hypochromic 43 morphological 281 \200\2238 prolymphocytic leukemia S St Jude staging 617 sarcoma 166, 168 \200\2239 prosthetic heart valves, abnormalities and variants 33 phenotyped 778 transfusion 562 \200\2234, 659, 536, 537 protein \200\223calorie Ewing 396 Kaposi 554, 557 mast cell 312, 319 osteogenic 396 soft cell 393 soft tissue 396 malnutrition 633 protein C defi ciency 530, 764 \200\2236 reduced intensity 531 protein S defi ciency 531,0, conditioning 389, 415 refractory anemia 230, 531 prothrombin gene mutation Savene 701 Schilling test 46 Schnitzler syndrome 369 Schumm \200\231s test 748 scurvy 633 Seattle protocol 424 Seckel syndrome 598 secondary eosinophilia 307 secondary erythrocytos is 624 530, 531 refractory anemia with prothrombin time 458 pseudo-Gaucher cells 634 pseudo-Pelger neutrophil excess blasts 230, 231, 624 \200\2235 refractory anemia 236 with excess blasts in transformation 230, 624 \200\2235 pseudopolycythaemia 10 pseudothrombocytopenia 462, 464 refractory anemia with pseudotumours 476 pseudo-vWD 485 psoriatic arthropathy 38 psychological support 673 pulmona ry embolism 518, 264 \200\2235, 278 senile purpura 20 septic shock (sepsis) 636 \200\2237, 684, 686 \200\223 7 serum ferritin 9, 43, 107 serum paraprotein 25 severe combined ringed sideroblasts 230, 231, 242, 243 refractory cytopenia with multilineage dysplasia (wi th ringed sideroblasts) 231 refractory cytopenia with unilineage dysplasia 230, 231 521 \200\2232 pure red cell aplasia 106 purine analogs, prophylaxis 688 purine nucleoside phosphorylase d efi ciency 546 immunodefi ciency (SCID) 546 \200\2237 sex hormones 36 S zary syndrome 167, 199, relative erythrocytosis 264, 265, 279 201, 205 \200\2236 sharps injury 708 Shwachman \200\223Diamond syndrome 597 \200\2238 sickl e/ thalassaemia renal cell cancer 393 renal disease 34 \200\2235, 498 reptilase time 459 respiratory syncyt ial virus purpura 18, 20 post-transfusion 492, 643 Purtilo syndrome 632 pyknocytosis, infantile 577 pyridoxine defi ciency 51 pyrimidine 5 \200\231 nucleotidase 687 65, 81 sickle/C 81 sickle cell anemia 56 \200\22360, reticular dysgenesis 546 reticulocyte Hb defi ciency 92 \200\2233 concentration 43 reticulocytes 33, 561, 749 retinoblastoma 608 retroperitoneal fi brosis 79 2 reverse transcriptase inhibitors 556 Revised International pyruvate kinase defi ciency 81 91 sickle cell disease 30, 395 sickle cells 33, 59 sickle cell trait 30, 64, 81 sickle crises 666, 672 sickle/D 81 sickle test 30 sickling disorders 56 \200\22365 Q quality of life 668 Prognostic Index 187 823 INDEX systemic mastocytosis with an associated hematological non- mast cell disease 312, 319 factors infl uencing outcome 390 fertility issues 450 foreign travel 449 fungal infections 442 \200\2234 graft-versus-host disease sinusoidal obstruction syndrome 438 \200\22340 slapped cheek 632 small cell lung cancer 393 small lymphocytic lymphoma systemic sclerosis 394 190, 192, 194 \200\2236 391, 428 \200\22336 smoking 10 smoldering chronic graft-versus-host disease prophylaxis 424 \200\2237 graft-versus-leukemia T tacrolimus 427 tapeworms 633 target cells 33 TAR syndrome 486, 596 TB 687 T-cell acute ly mphoblastic leukemia 144, 755 lymphocytic leukemia 162 eff ect 388 HLA hierarchy 398 indications 392 \200\2236 investigations 404 \200\2235 JACIE accreditation 388 longer term eff ects 450 non-cryopreserved stem cell infusion 418 periphe ral blood stem cell mobilization and harvesting 388, 410 \200\22311 post-transplant smoldering myeloma 25, 332 \200\2234 smoldering systemic mastocytosis 319 sodium chlorate 634 soft cell sarcoma 393 soft tissue sarcoma 396 Sokol Score 151, 808 solitary extraosseous T-cell large granular lymphocyte leukemia 167, 174 \200\2235 plasmacytoma 366 \200\2237 solitary mastocytoma 313 solitary plasmacytoma of T-cell prolymphocytic leukemia 167 T-cell rich B-cell lymphoma bone 366 198 T cells 118 teardrop red blood cells 33 TET2 261 thalassaemias 70 \200\2239 vaccination 448 \200\2239 soluble transferrin assay 43 Southeast Asian pretransplant investigation of donors 406 reduced intensity ovalocytosis 87 spherocytes 33 spherocytic hereditary elliptocytosis 87 thalassaemia 72 \200\2233, 81 thalassaemia 74 \200\2238, conditioning 389, 415 relapse, post-allogeneic spherocytosis, hereditary 79, 81 transplant 451 RhD mismatch 422 sinusoidal obstruction syndrome 438 \200\22340 umbilical co rd blood 400 veno-occlusive disease 84 \200\2236 thalassaemia 79 thalassaemias 79 stem cell transplant 395, spinal collapse 662 splenic marginal zone lymphoma 166, 190 \200\2231, 192, 197 splenomegaly 5 spur cell anemia 41 spurious polycytha emia 10 SQUID 108 Stanford V 743 \200\2234 starvation 51 stem cell leukemia- lymphoma 308 414 thrombin generation 456, 457 438 \200\22340 thrombin time 459 thrombocythaemia, essential 281 \200\2238 thrombocytopenia 18 storage disorders 395, 634 storage pool disorders 464, 486 stress polycythaemia 10 subacute necrotizing lymphadenitis 789 acquired 490 \200\2231 congenital 485 congenital sucrose lysis 751 supportive care 667 \200\22373 surgery stem cell transplantation amegakaryocytic 596 diff erential diagnosis 19 drug-induced 468, 492 \200\2233 heparin-indu ced 512, 542 \200\2233, 654 \200\2235, 704 387 \200\223452 ABO mismatch 421, 422 allogeneic 389, 398 \200\223400, bleeding 28 \200\2239, 467, 506 \200\2237 intra-operative cell salvage 777 448 autologous 389, 402, 449 blood product support hypersplenism 492 liver disease 496 neonatal alloimmune 485, Jehovah \200\231s Witnesses 780 \200\2231 420 \200\2232 maximum surgical blood ordering schedule 778 bone marrow harvesting 586 \200\2237 388, 408 \200\2239 pregnancy 27, 492 TAR syndrome 486, 596 oral anticoagulation 515 pre-operative CMV 446 \200\2237 complications 390 \200\2231 conditioning 389, 399, thrombocytosis 16 \200\22317 thromboelastography 459 thrombolytic therapy overdosage 651 th rombophilia 454 haemodilution 777 thromboprophylaxis 414 \200\22315 525 \200\2236 cryopreserved stem cells symptoms, presenting 2 \200\2233 systemic lupus 412, 416 \200\22317 discharge and follow-up acquired 454, 534 \200\2237 heritable 530 \200\2232 thromboplastin 458 thromboprophylaxis 5 24 \200\2236 erythematosus 632 systemic mastocytosis 312, 391, 452 donor lymphocyte infusion 451 316 \200\22322 824 INDEX U umbilical cord transplants Waldeyer \200\231s ring 185 warfarin 514 \200\22315, 536, 706 thrombosis 22, 518 \200\22322 essential overdosage 656 thrombocythaemia 288 400 warm antibody induced haemolysis 98 \200\2239 \200\230washed \200\231 platelets 769 websit es 796 \200\223801 Well \200\231s score 519 white blood cell count unfractionated heparin 510, risk assessment 524 \200\2236, 704 \200\2235 528, 529 uraemic bleeding 498 urine thrombotic thrombocytopenic purpura 538 \200\2239, 664 \200\2235 alkalinization 691 haemosiderin 750 paraprotein 25 children 560 elevated 12 \200\22313 reduced 14 \200\22315 thyroid disorders 36 thyrotoxicosis 36 tissue factor 456 TORCH infections 632 tramadol 671 tranexamic acid 470, 659, urticaria pigmentosa 632 WHO-based Prognostic Scoring System (WPSS) 240 V variant CJD 479, 747 vegans 8, 46, 633 vena cava fi lters 522 veno-occlusive disease WHO classifi cation 777 lymphoid neoplasms 182, transcobalamin II defi ciency 183 \200\2234 50 mastocytosis 312 myelodysplastic % transferrin saturation 108 438 \200\22340 syndromes 230, 231 transfusion-associated venous thromboembolism myeloproliferative neoplasms 258 circulatory overload 639 518 \200\22322, 536 transfusion-associated graft-versus-host disease 775 risk assessment 524 \200\2236, WHO/ECOG 528, 529 performance status 804 verocytotoxin 540, 606 viral hepatitis 41 vitamin A defi ciency 51 vitamin B6 defi ciency 5 1 vitamin B12 defi ciency 46 \200\2237 vitamin C defi ciency 51 vitamin E defi ciency 51 vi tamin K WHO hematological toxicity scale 805 transfusion haemosiderosis 77, 110 \200\22311 Wilms tumor 396 Wilson disease 83, 632 Wiskott \200\223Aldrich syndrome transfusion reactions 638 \200\22340, 641, 642 transfusion-related acute 547 lung injury 638 transfusion transmitted infections 774 \200\2235 transient abnormal myelopo iesis 625 neonatal defi ciency 488, X X-linked 584 warfarin therapy 656 vitamin K antagonists 514 \200\22315, 706 transient agammaglobulinaemia 548 erythroblastopenia of childhood 592 \200\2233 von Willebrand disease